Royalty Pharma plc (RPRX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $52.46 — A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (2.0% away).
Royalty Pharma is the largest buyer of biopharmaceutical royalties, holding a portfolio of 35+ marketed therapies including Vertex's cystic fibrosis franchise, GSK's Trelegy, and Biogen's Tysabri. In 2025, it generated $3.3B in Portfolio Receipts and deployed $2.6B to acquire... Read more
Sell if holding. Analyst target reached at $52.46 — A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (2.0% away). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Royalty Pharma plc
Latest news
- Royalty Pharma (RPRX) to Release Earnings on Wednesday - MarketBeat — MarketBeat neutral
- Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance — Yahoo Finance positive
- Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year High - Should You Buy? - MarketBeat — MarketBeat positive
- Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week High - Still a Buy? - MarketBeat — MarketBeat positive
- Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings - TradingView — TradingView positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductcystic fibrosis franchise10-K Item 1: 'Cystic fibrosis franchise(2)| Vertex| Rare disease| Cystic fibrosis| $917| $11,725'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $52.46 — A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (2.0% away). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $50.13. Score 5.3/10, moderate confidence.
Take-profit target: $52.27 (-0.3% upside). Prior stop was $50.13. Stop-loss: $50.13.
Analyst target reached - limited upside remaining; Near 52-week high (2.0% away); Consecutive earnings misses (2).
Royalty Pharma plc trades at a P/E of 27.6 (forward 9.3). TrendMatrix value score: 4.9/10. Verdict: Sell.
16 analysts cover RPRX with a consensus score of 4.2/5. Average price target: $59.
What does Royalty Pharma plc do?Royalty Pharma is the largest buyer of biopharmaceutical royalties, holding a portfolio of 35+ marketed therapies...
Royalty Pharma is the largest buyer of biopharmaceutical royalties, holding a portfolio of 35+ marketed therapies including Vertex's cystic fibrosis franchise, GSK's Trelegy, and Biogen's Tysabri. In 2025, it generated $3.3B in Portfolio Receipts and deployed $2.6B to acquire new royalties. Revenue is royalty payments tied to the top-line sales of funded therapies.